Abstract. We evaluated changes in the binding properties of sedative and non-sedative histamine H 1 -receptor antagonists induced by internalization of H 1 receptors in intact human U373 MG astrocytoma cells. Internalization of H 1 receptors was induced without their degradation by treatment with 0.1 mM histamine for 30 min at 37°C, and then the intact cell binding assay was performed at 4°C. The binding properties of [
Introduction
The blood-brain barrier is a diffusion barrier that impedes the influx of most compounds from the blood to brain (1) . Classical histamine H 1 -receptor antagonists are well known to have side effects such as sedation and hypnosis, which are associated with the blockade of central H 1 receptors. Second or new generation H 1 -receptor antagonists, so-called non-sedative antihistamines, have fewer side effects on the central nervous system as a result of less blockade of central H 1 receptors, although they might induce sedation at higher doses. Detection of H 1 -receptor occupancy in the human brain by positron emission tomography (PET) is proposed to identify a consensus group of new-generation antihistamines (CONGA) (2), but not all antihistamines have been examined as to whether they fulfill CONGA criteria.
Non-sedative H 1 -receptor antagonists such as mequitazine and loratadine were reported to have lower affinity for central than peripheral H 1 receptors (3, 4), but there is convincing evidence that there is no difference in the affinity of non-sedative H 1 -receptor antagonists such as terfenadine, astemizole, loratadine, epinastine, temelastine, and cetirizine for central and peripheral H 1 receptors (5) . There are several reports that the affinity for the P-glycoprotein efflux pump in endothelial cells at the blood brain barrier may explain the lack of CNS side effects of non-sedative H 1 -receptor antagonists due to their extrusion from the brain (6 -8) ; however, Pglycoprotein-mediated extrusion alone seems not wholly to explain their non-sedative behavior, since terfenadine, for example, is reported to distribute at a high concentration in the brain as well as in the plasma due to its high passive permeability to overcome P-glycoproteinmediated efflux (9) . The passive membrane permeability of H 1 -receptor antagonists may therefore be an important parameter to assess with respect to their non-sedative characteristics.
The lipophilicity of antihistamines, including the proportion of their uncharged form at physiological pH, is a key property for their ability to cross the biomembrane as well as the blood-brain barrier, but lipophilicity alone does not explain their lack of penetration. A combination of parameters such as the octanol / water distribution coefficient at pH 7.4 and hydrogen-bonding and hydration capacity is also important in assessing membrane-penetrating ability (10) . However, the variety of chemical structures and physicochemical properties of antihistamines makes it difficult to accurately predict their ability to penetrate the biomembrane. It would greatly contribute to the development of novel antihistamines if more direct information on their membrane-penetrating properties could be obtained from a simple in vitro assay, before the use of in vivo assessments of their penetration into the brain, such as the measurement of subjective sleepiness or brain histamine H 1 -receptor occupancy using 11 C-doxepin positron emission tomography (11) .
G protein-coupled receptors are known to undergo a process of agonist-induced sequestration or internalization, moving from the cell surface via the formation of endosomes into an intracellular compartment inaccessible to extracellular ligands unable to cross the cell membrane (12 -16) . We have established an intact cell binding method to evaluate the number of G q proteincoupled histamine H 1 receptors on the cell surface in human U373 MG astrocytoma cells by using pirdonium, an H 1 -receptor antagonist with a permanently charged quaternary ammonium group, to define the binding of a cell-penetrant radioligand, [ 3 H]mepyramine, to cell surface H 1 receptors (17, 18) . In these measurements, internalization of H 1 receptors was monitored as a decrease in pirdonium-sensitive [
3 H]mepyramine binding and an equivalent increase in pirdonium-insensitive binding, whereas total [ 3 H]mepyramine binding measured in the absence of pirdonium and the total amount of cellular proteins were not changed. The histamineinduced internalization of H 1 receptors has been confirmed by measuring the change in the subcellular distribution of H 1 receptors, using sucrose density gradient centrifugation, and by inhibition of histamine-induced reduction in the pirdonium-sensitive binding of [ 3 H]mepyramine under conditions where clathrin-mediated internalization was inhibited (18) . Thus, the effect of receptor internalization on the binding properties of receptor ligands will depend on their ability to penetrate the biomembrane. We therefore tested how receptor internalization influenced the binding properties of a variety of H 1 -receptor antagonists. In this report, we present our findings that there were clear differences between the effect of histamineinduced H 1 -receptor internalization on the inhibition of [ 3 H]mepyramine binding by sedative and non-sedative H 1 -receptor antagonists in intact cells, which may provide a simple in vitro assay to predict the properties of drugs to penetrate the biomembrane or possibly the blood-brain barrier.
Materials and Methods

Materials
Mepyramine maleate, (±) chlorpheniramine maleate, diphenhydramine hydrochloride, promethazine hydrochloride, and ketotifen fumarate were purchased from Sigma-Aldrich (Tokyo); [pyridinyl- 
Cell preparation for intact cell binding assay
Human U373 MG astrocytoma cells (National Culture Collection, Porton Down, UK) were cultured in 150-cm 2 culture flasks as described previously (17) . Dissociated cells were suspended in normal HEPES buffer (120 mM NaCl, 5.4 mM KCl, 1.6 mM MgCl 2 , 1.8 mM CaCl 2 , 11 mM D-glucose, and 25 mM HEPES, pH 7.4 at 37°C) and kept at 37°C for 30 min for equilibration. For induction of receptor internalization, the cells (circa 1 × 10 7 cells/ml) were incubated with 0.1 mM histamine for 30 min at 37°C in normal HEPES buffer. In experiments on the effect of hypertonic medium, cells were treated with or without 0.1 mM histamine for 30 min in normal and hypertonic HEPES buffer (320 mM sucrose was added to normal HEPES buffer). Control and histamine-treated cell suspensions were then diluted 4.75-fold with ice-cold HEPES medium and centrifuged at 220 × g for 5 min. The cells were washed by suspending them twice in 30 ml ice-cold medium and centrifuging at 220 × g for 5 min, before resuspending them in 4.7 ml ice-cold medium. The protein content of each cell suspension was determined at this stage. 3 H]mepyramine / HEPES medium. The reaction mixture was diluted 4-fold with ice-cold normal HEPES buffer and centrifuged at 220 × g for 5 min at 4°C. The cells were resuspended in 3 ml ice-cold buffer and the suspension was filtered through Whatman GF /B glass fiber filters (pre-soaked for at least 3 h in 0.3% polyethylenimine) using a 24-place cell harvester (Brandel, Gaithersburg, MD, USA). The filters were transferred to scintillation vial inserts, 3 ml scintillator added, and the vials allowed to stand for at least 2 h before determination of tritium by scintillation counting. Whole cell protein was determined essentially as described by Lowry et al. (19) . The total binding of 1 -10 nM [ 3 H]mepyramine in control preparations was approximately 100 -300 dpm /vial.
Data analyses
All the data are presented as the mean ± S.E.M. of at least three measurements performed in quadruplicate. Statistical significance was evaluated by Student's t test. A value of P<0.05 was considered statistically significant.
In the initial saturation experiments, the number of histamine H 1 receptors was determined by fitting (KaleidaGraph; Synergy Software, Reading, PA, USA) the mepyramine-or pirdonium-sensitive binding of One-site model: B = 100 − P × IC / (C + IC) Two-site model: To construct theoretical displacement curves with two affinity sites, the IC H value was kept at 10 −7.5 with varying IC L values from 10 −4.5 to 10 −6.5 , and P H and P L values were set at either 70% and 30% or 30% and 70%, respectively.
Results
Effect of histamine pretreatment on mepyramine-sensitive [
3 H]mepyramine binding To elucidate whether down-regulation of histamine H 1 receptors occurs after pretreatment with 0.1 mM histamine for 30 min in human U373 MG astrocytoma cells, we first examined histamine-induced changes in the number of cellular histamine H 1 receptors by measuring B max values for the 10 μM mepyramine-sensitive binding of [ 3 H]mepyramine binding was dramatically increased by histamine treatment (Fig. 1c) , with a consequent decrease in pirdonium-sensitive binding (Fig. 1d) . The estimated B max value for pirdonium-sensitive [
3 H]mepyramine binding to histamine pretreated cells was 9.0 ± 0.7 fmol /mg whole cell protein (n = 6), which corresponded to approximately 40% of pirdonium-sensitive [ for histamine-pretreated cells (n = 6). These values were also not significantly different from those for mepyramine-sensitive sites.
Effect of histamine pretreatment on the inhibition of [
3 H]mepyramine binding by mepyramine and pirdonium Histamine-induced changes in the displacement curves for mepyramine and pirdonium against the binding of 5 nM [
3 H]mepyramine were examined. The displacement curves for mepyramine were best fitted to a one-site model, and there were no significant changes in the pIC 50 values for mepyramine by pretreatment of the cells with 0.1 mM histamine for 30 min (Fig. 2a , Table 1 ). In contrast, the displacement curves for pirdonium were best fitted to a two-site model and the effect of histamine pretreatment was to reduce the proportion of the high affinity site, with a concomitant increase in the proportion of the low affinity site (Fig. 2b , Table 1 ).
3 H]mepyramine binding by sedative H 1 -receptor antagonists The displacement curves for sedative H 1 -receptor antagonists, diphenhydramine, (±) chlorpheniramine, and promethazine, were best fitted to a one-site model, which were not changed by histamine pretreatment, with no significant changes in the pIC 50 values for these antagonists (Fig. 3 , Table 1 ). The displacement curves and pIC 50 values for other sedative H 1 -receptor antagonists, ketotifen, azelastine, and oxatomide, were also unaffected by histamine pretreatment (Fig. 3 , Table 1 ).
3 H]mepyramine binding by non-sedative H 1 -receptor antagonists In striking contrast to sedative H 1 -receptor antagonists, the displacement curves for non-sedative H 1 -receptor antagonists, mequitazine (3), bepotastine (20, 21) , olopatadine (22) , and epinastine (23, 24) , were changed by histamine pretreatment (Fig. 4) . The displacement curves for mequitazine and bepotastine (Fig. 4 : a and b) were both best fitted to a one-site model, with the curves shifted to the right by histamine treatment, that is, pIC 50 values were significantly decreased (Table 1 ). In contrast, for olopatadine and epinastine (Fig. 4: c and d) , the displacement curves were best fitted to a two-site model and the effect of histamine pretreatment was to reduce the proportion of the high affinity site, with a concomitant increase in the proportion of the low affinity site ( Table 1) .
3 H]mepyramine binding by ebastine, loratadine, and terfenadine and by their active metabolites, carebastine, desloratadine, and fexofenadine
To further test differences between the binding properties of antihistamines and their active metabolites with very close structures, we compared the effects of histamine pretreatment on the displacement curves for ebastine, loratadine, and terfenadine and for their nonsedative active metabolites, carebastine, desloratadine, and fexofenadine, respectively (7, 25 -30) . The displacement curves for ebastine, loratadine, and terfenadine were best fitted by a one-site model and were not changed by histamine pretreatment (Fig. 5: a, c , and e; Table 1 ), as with the other sedative H 1 -receptor antago- (Fig. 3, Table 1 ). On the other hand, the displacement curves for carebastine and desloratadine, which were also fitted to a one-site model, were shifted to the right by histamine pretreatment (Fig. 5: b and d) , with a significant decrease in the pIC 50 value (Table 1) , in a similar manner to non-sedative mequitazine and bepotastine (Fig. 4: a and b, Table 1 ). In contrast, the displacement curves for fexofenadine (Fig. 5f) were best fitted to a two-site model and histamine pretreatment reduced the proportion of the high affinity site with a concomitant increase in the proportion of the low affinity site (Table 1) , in a similar manner to non-sedative olopatadine and epinastine (Fig. 4: c and d, Table 1 ).
Effects of hypertonic conditions on the inhibition curves for pirdonium, epinastine, and carebastine of [ To elucidate whether histamine-induced changes in the two types of displacement curves for non-sedative H 1 -receptor antagonists were a consequence of histamine-induced receptor internalization, we examined the effect of hypertonic conditions, HEPES buffer containing 320 mM sucrose, which are known to inhibit the formation of clathrin-coated vesicles (31) and H 1 -receptor internalization (18) , in the inhibition of [ 3 H]mepyramine binding by pirdonium, epinastine, and carebastine (Fig. 6) . Hypertonic medium pretreatment of cells with histamine now had no effect on these inhibition curves, with no significant changes in the proportion of high and low affinity sites and the corresponding pIC 50 values for pirdonium and epinastine or in pIC 50 values for carebastine (Table 1) .
Theoretical prediction of changes in displacement curves induced by changes in the proportion of high and low affinity sites
To assess whether monophasic and biphasic curves for non-sedative H 1 -receptor antagonists were determined by the extent of difference between IC 50 values for high and low affinity sites, theoretical displacement curves were constructed. Figure 7 shows the theoretical displacement curves for a drug, where the proportion of high and low affinity sites for the drug was set at 70% and 30% (open symbol) or 30% and 70% (closed symbol), respectively. Each point represents the theoretical value obtained by a two-site model. When the difference between IC 50 values for high and low affinity sites was reduced from 1000-fold to 100-or 10-fold by changing pIC 50 values for the low affinity site from 4.5 to 5.5 or 6.5 with a constant pIC 50 value of 7.5 for the high affinity site, the two phases became obscure to apparently yield a monophasic-like curve ( Fig. 7: a, b and c; open circle).
When a drastic decrease and a concomitant increase were induced in the proportion of high and low affinity sites, respectively, the theoretical curves in Fig. 7a , where a 1000-fold difference existed between the IC 50 values for these sites, showed a change similar to those observed for histamine-induced changes in the biphasic curves for pirdonium (Fig. 2b) , olopatadine, and epinastine (Fig. 4: c and d) , where 350-to 800-fold differences existed between their IC 50 values for high and low affinity sites (Table 1) .
The theoretical curves in Fig. 7 : b or c, where a 100-or 10-fold difference existed between the IC 50 values for these sites, showed similar changes to those observed for histamine-induced changes in the biphasic curves for fexofenadine (Fig. 5f) , where approximately a 60-fold difference existed between its IC 50 values for these two affinity sites (Table 1) .
When the theoretical points plotted in Fig. 7c were rendered to fit to a one-site model (Fig. 7d) , monophasic curves were accordingly obtained, and a 2.7-fold parallel shift of the curve was induced by reversal of the proportion of the high and low affinity sites. It is noted that such a theoretical change is remarkably similar to that actually observed in the monophasic curves for mequitazine, bepotastine, carebastine, and desloratadine, which showed approximately a 3-fold shift of the monophasic curves to the right by the histamine treatment ( Internalization-mediated changes in displacement curves for sedative and non-sedative H 1 -receptor antagonists The binding affinities for sedative H 1 -receptor antagonists, diphenhydramine (an ethanolamine derivative), (±) chlorpheniramine (a propylamine derivative), and promethazine (a phenothiazine derivative) against [ 3 H]mepyramine binding were not changed by histamine pretreatment, in a manner similar to those for mepyramine (an ethylenediamine derivative) and irrespective of differences in their chemical structures. The same results were obtained with another set of sedative H 1 -receptor antagonists, ketotifen, azelastine, and oxatomide, which are known to inhibit histamine release from mast cells in addition to H 1 -receptor blockade (32 -34) . The results indicate that the binding of these sedative H 1 -receptor antagonists to H 1 receptors was unaffected by histamine-induced receptor internalization, implying that they could pass through the biomembrane and bind to internalized H 1 receptors with an affinity similar to that for cell surface H 1 receptors.
In striking contrast, the displacement curves for nonsedative H 1 -receptor antagonists were changed by histamine pretreatment. Two types of changes were observed with histamine pretreatment: displacement curves for mequitazine, bepotastine, carebastine, and desloratadine were best-fitted to a one-site model, and the displacement curves were shifted to the right after histamine pretreatment. In contrast, the displacement curves for olopatadine, epinastine, and fexofenadine were bestfitted to a two-site model, and histamine pretreatment induced a reduction in the proportion of the high affinity site and a concomitant increase in that of the low affinity site for these antagonists, in a manner similar to the case for pirdonium. It is most likely that these two types of changes were caused by internalization of H 1 receptors, since these changes were completely inhibited under hypertonic conditions, where the internalization of H 1 receptors was known to be inhibited. It is reported that histamine-induced internalization of Myc-GFP-tagged H 1 receptors, which were over-expressed in CHO-K1 cells, was not inhibited under hypertonic conditions (35) . This is in contrast to our results with human astrocytoma cells that natively express H 1 receptors. It remained to be elucidated whether such differences in internalization mechanisms might result from differences between cell types or expression levels of H 1 receptors or from modification of H 1 -receptor molecules with Myc and / or GFP.
Since the evidence shows that histamine-induced changes are only observed for non-sedative compounds, it may reflect an access limitation of these non-sedative compounds to intracellular receptors. Non-sedative H 1 -receptor antagonists, however, do not have common chemical structures, and it is possible that different amino acid residues of the histamine H 1 receptor are responsible for their binding. Accordingly, we cannot exclude the possibility that internalized H 1 -receptor molecules are conformationally changed to result in the reduced affinity for non-sedative H 1 -receptor antagonists, although these non-sedative H 1 -receptor antagonists are required to penetrate the membrane before reaching the binding sites of internalized H 1 receptors.
Two types of displacement curves for non-sedative H 1 -receptor antagonists
High and low affinity sites for olopatadine, epinastine, or fexofenadine showed exactly the same difference observed between tertiary amine antagonists and their quaternary derivatives, including pirdonium and norpirdonium (17) , yet the percentage of the binding of [ 3 H]mepyramine insensitive to inhibition is approximately the same, irrespective of whether the antagonists are tertiary or quaternary amines (17) or sedative or non-sedative (Table 1 ). This suggests that the secondary site is intracellular, but there is only sufficient intracellular compound for inhibition to be observed during the experiment at higher extracellular concentrations of antagonist. Namely, non-sedative H 1 -receptor antagonists appeared to have a lower affinity for intracellular H 1 receptors than cell surface H 1 receptors, possibly due to their lower ability to penetrate the cell membrane. Fig. 7 . Theoretical prediction of changes in the displacement curves by changes in the proportion of high and low affinity sites. Displacement curves show theoretical displacement curves for a drug with a 1000 (a)-, 100 (b)-, or 10 (c)-fold difference between its IC50 values for high and low affinity sites: The pIC50 value for the high affinity site was 7.5 (a -c), while that for the low affinity site was set at 4.5 (a), 5.5 (b), and 6.5 (c). The proportions of high and low affinity sites were 70% and 30% (open symbol) or 30% and 70% (closed circle), respectively. Each point represents the theoretical value obtained by a two-site model. When the theoretical points plotted in (c), where the difference between high and low affinity sites was fixed at 10-fold, were rendered to fit to a one-site model (d), a 2.7-fold parallel shift of the monophasic curve was obtained due to a theoretical increase and a corresponding decrease in the proportion of low and high affinity sites, respectively.
Monophasic curves for mequitazine, bepotastine, carebastine, and desloratadine seem to imply that these compounds do not well distinguish the two sites as detected by olopatadine and epinastine. Yet the curves for these non-sedative compounds were shifted a few fold to the right by histamine pretreatment. We consider, therefore, that there is a small but definite difference in the affinity of these compounds for H 1 receptors on the cell surface and intracellularly. The possibility must be considered that these compounds bind to such a heterogeneous population of H 1 receptors and that the drastic increase in the proportion of intracellular H 1 receptors with a lower affinity for these compounds may bring about such a rightward shift in their displacement curves. This assumption is strongly supported by the theoretical curves, where the apparent shape of curves, that is, monophasic or biphasic, was determined by the extent of difference between IC 50 values for high and low affinity sites. When there was a large difference (1000-fold) between IC 50 values for high and low affinity sites, these two sites could be clearly differentiated by the two-site model and a drastic increase in the proportion of the low affinity site with a concomitant decrease in the proportion of the high affinity site induced a theoretical change similar to that actually observed in the biphasic curve for olopatadine or epinastine. In contrast, when there was a much smaller difference (10-fold) between IC 50 values for high and low affinity sites, the curves became monophasic-like. These two affinity sites could be correctly determined by the two-site model with theoretical data, but not with actual data with errors. When theoretical data with two affinity sites were rendered to fit to a one-site model, a rightward shift of the monophasic curves was obtained by drastic changes in the proportion of high and low affinity sites. This change was exactly what we observed in monophasic curves for mequitazine, bepotastine, carebastine, and desloratadine; that is, internalizationmediated changes in the proportion of high and low affinity sites could also be reflected in the rightward shift in the monophasic curve. Furthermore, these theoretical analyses suggest that when data were fitted to the onesite model, the fixed change in the proportion of high and low affinity sites resulted in a rightward shift of monophasic curves by only a few fold, even though a 10-fold difference was set to exist theoretically between IC 50 values for high and low affinity sites. Namely, a few-fold rightward shift of a monophasic curve for mequitazine, bepotastine, carebastine, and desloratadine suggests that these drugs have a much lower affinity for intracellular H 1 receptors, that is, much less ability to penetrate the biomembrane than we observed, which might well account for their non-sedative behavior.
It is unclear, however, whether clinical differences might exist between these two groups of non-sedative antihistamines showing monophasic and biphasic curves. Since the clinical differences might be affected by individual differences of subjects as well as differential conditions set out in trials, this intact cell binding assay may have the advantage of providing valuable information on potential differences among nonsedative antihistamines that may clinically exist.
Membrane penetration of H 1 -receptor antagonists and their extrusion via P-glycoprotein Ebastine, loratadine, and terfenadine and their active metabolites, carebastine, desloratadine, and fexofenadine, were reported to be substrates for P-glycoprotein (7, 26, 27) ; however, desloratadine is also reported not to be a significant substrate for P-glycoprotein (28, 29) . Such an inconsistency possibly results from different assay systems used to determine the involvement of Pglycoprotein (30) . Furthermore, terfenadine is reported to distribute at a high concentration in the brain as well as in the plasma due to its high passive permeability to overcome P-glycoprotein-mediated efflux (9) . The nonsedative behavior of ebastine is also reported to be due to its metabolite, carebastine (25) . Thus, there is no Fig. 8 . A scheme for explaining internalization-mediated changes in the binding properties of sedative and non-sedative H1-receptor antagonists. Sedative H1-receptor antagonists appear to easily pass through the cell membrane so as to bind to the cell surface and intracellular H1 receptors with similar affinities; thereby, their binding properties are not affected by internalization of H1 receptors. On the contrary, non-sedative H1-receptor antagonists appear to pass through the cell membrane only at higher concentrations so as to bind to the intracellular H1 receptors with lower affinities than to those on the cell surface; thereby, their binding properties are dramatically changed by internalization of H1 receptors.
convincing evidence that ebastine, loratadine, or terfenadine itself is really non-sedative; and their major effects are reasonably due to the action of their corresponding active metabolite. Since the displacement curves for ebastine, terfenadine, and loratadine were not at all changed by the histamine-induced internalization of H 1 receptors, these drugs appeared to have free access to internalized H 1 receptors through the plasma membrane. In contrast, carebastine, desloratadine, and fexofenadine appear to have a lower ability to penetrate the biomembrane. This might explain why ebastine showed a larger brain uptake than carebastine, even though the brain uptake of ebastine was more effectively influenced than carebastine in mdr1a(−/−) mice (26) . Thus, we estimate that the movement of H 1 -receptor antagonists into the brain may be predominantly regulated by their passive permeability rather than their active extrusion via the P-glycoprotein pump. We emphasize that such an in vitro evaluation of the membrane permeability of H 1 -receptor antagonists by intact cell binding assay may provide an important aspect of their sedative and nonsedative characteristics, being a more reliable parameter than whether they are substrates for the P-glycoprotein extrusion pump.
Conclusions
Sedative and non-sedative H 1 -receptor antagonists, which have various chemical structures and physicochemical properties, were successfully distinguished in a simple in vitro assay by measuring internalizationmediated changes in their binding to H 1 receptors in intact cells (Fig. 8 ). This intact cell binding assay may be the simplest system for the simultaneous evaluation of membrane-penetration properties of H 1 -receptor antagonists and their binding properties to H 1 receptors to predict sedative and non-sedative behaviors, even though the blood brain barrier expresses structural and functional characteristics different from dissociated astrocytoma cells, including the formation of a tight junction between endothelial cells to restrict the penetration of drugs into the brain. Furthermore, our results suggest that this intact cell binding method based on receptor internalization may be widely applicable to drugs acting on a variety of receptors for in vitro prediction of their permeability through the cell membrane and possibly the blood brain barrier.
